Abstract
Background: Medication adherence is critical for success of clinical trials. Objective: To assess oral riboflavin is an adherence marker. Methods: Riboflavin was incorporated into active treatment and placebo pills for a clinical trial lasting for 2 years. Results: The accuracy (area under the receiver operating curve) of urinary riboflavin was 0.91 as a binary classifier of adherence, and was similar or better than for two active study ingredients daidzein (0.92) and genistein (0.87) (all p < 0.0001). Decreased adherence over time was similar in the two study groups. Conclusion: Riboflavin is an accurate and useful biomarker for study pill ingestion.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 508-516 |
| Number of pages | 9 |
| Journal | Biomarkers |
| Volume | 22 |
| Issue number | 6 |
| DOIs | |
| State | Published - Aug 18 2017 |
Keywords
- Biomarker
- accuracy
- adherence
- clinical trial
- daidzein
- genistein
- medication compliance
- receiver operating curve
- riboflavin
- sensitivity
- specificity
ASJC Scopus subject areas
- Biochemistry
- Clinical Biochemistry
- Health, Toxicology and Mutagenesis